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Cancer is a group of conditions in which cells 
acquire a constellation of traits that in the 
course of carcinogenesis, enables them to sur-
vive, achieve sustained chronic proliferation 
and disseminate. To attain such unremitting 
subsistence, the tumor cells take advantage of 
complex cell biological networks that include, 
but are not limited to: dysregulation of growth-
promoting signaling pathways; attenuation of 
proliferative negative-feedback mechanisms; 
evasion of growth suppressors; blunting of cell 
attachment; and circumventing the immune 
system. Notably, these traits are further culti-
vated by rampant genetic instability as high-
lighted by the generation of random  mutations 
and chromosomal  rearrangement.
In the USA, cancer is the second leading 
cause of death – second only to cardiovascu-
lar disease. Sadly, and quite profoundly, this 
complex disease touches millions of lives, and 
continues to be an immense burden for pub-
lic health systems and economies world-wide. 
Putting this into perspective, for the year 
2016, the American Cancer Society has pro-
jected a total of 1,685,210 new cancer cases 
(the equivalent of 4600 new cancer diagno-
ses/day) [1], and 595,690 of cancer deaths 
(corresponding to 1600 deaths/day).
Current challenges in cancer 
treatment
It is undeniable that enormous strides have 
been made by clinicians and biomedical 
researchers in the pursuit of combating neo-
plastic disease, and such successes have and 
will continue to advance diagnostic and 
therapeutic development. Current thera-
peutic approaches tailored to the molecular 
determinants that drive tumor growth, have 
resulted in improvement in treatment out-
comes of various types of cancer. For exam-
ple, HER2, a receptor that drives and acti-
vates proliferation/survival pathways such as 
MAPK and PI3K/Akt, has been the target 
of multiple adjuvant drugs used in breast 
and gastric neoplasias. However, anti-HER2 
monoclonal antibodies that are currently 
on the market have only yielded moderate 
improvements in clinical outcomes [2], and 
are documented to be associated with severe 
cardiotoxic events [2]. Additional dysregu-
lated oncogenic signaling pathways, such as 
antiapoptotic signals, tumor-driven angio-
genesis and increased immune evasion, have 
been the focus of targeted cancer therapies 
with mixed grades of success. Therefore, 
any lack of therapeutic success can likely 
be broadly explained by the complex nature 
of the disease, its heterogeneous presenta-
tion and the fundamental ability of cancer 
cells to constantly evolve, adapt and switch 
dependency on different oncogenic signal-
ing pathways. Nevertheless, the desirability 
of targeted therapies lies in their ability to 
arrest tumor growth and induce regression, 
as observed in a molecularly defined cohort 
Can a nanoparticle that mimics Salmonella 
effectively combat tumor chemotherapy 
resistance?
“...engineering of this semisynthetic Salmonella nanoparticle mimic 
introduces a new platform technology that has the capacity to 
be applied to various chemotherapeutic drugs to overcome MDR 
in tumors.”
Regino Mercado-
Lubo 
Department of Microbiology 
& Physiological Systems, 
University of Massachusetts 
Medical School, 368 
Plantation Street, Worcester, 
MA 01655, USA
Beth A McCormick
Author for correspondence: 
Department of Microbiology 
& Physiological Systems, 
University of Massachusetts 
Medical School, 
368 Plantation Street, 
Worcester, MA 01655, USA 
Tel.: +1 508 856 6048 
Fax: +1 508 856 3355 
Beth.McCormick@
umassmed.edu
For reprint orders, please contact: reprints@futuremedicine.com
706 Nanomedicine (Lond.) (2017) 12(7) future science group
Commentary    Mercado-Lubo & McCormick
of patients. However, if used alone, such treatment 
regimens often fail to kill tumor cells, which notably 
underscores a critical need for chemotherapeutic drugs 
in the treatment of cancer patients.
Among the different types of cancer therapies avail-
able today (e.g., surgery, radiotherapy, immunotherapy 
and targeted therapies), chemotherapy continues to be 
one of the first lines of treatment (and in some cases, 
the only feasible option). In instances like advanced 
or metastasized breast cancer, chemotherapy regimens 
typically include drugs within the taxane and anthra-
cycline families, along with targeted therapy directed 
against the estrogen receptor, the progesterone recep-
tor, or HER2. However, the effectiveness of such cyto-
toxic drugs is often restricted by two key factors: resis-
tance to chemotherapeutic agents; and the devastating 
side effects triggered by them.
Patients undergoing chemotherapy also face signifi-
cant side effects that adversely impact their quality of 
life. Chemotherapy-induced gastrointestinal complica-
tions, reduced blood cell counts, infections and fever, 
electrolyte disorders, malnutrition, peripheral neu-
ropathy and premature menopause in women are com-
mon among patients being treated for cancer [3], with 
younger patients showing greater psychological mor-
bidity [3]. These side effects often debilitate patients and 
are an unfortunate limiting step in cancer management. 
Not surprisingly, chemotherapy-induced side effects are 
considered to be one of the principal burdens faced by 
both patients and clinicians. While the large major-
ity of cancer-related hospitalizations are precipitated 
by the disease itself, approximately 30% are triggered 
by adverse effects from the treatment [4]. Recent stud-
ies have also suggested that the chemotherapy-related 
side effects may be more common than what is reported 
by large clinical trials, and lead to more patient suffer-
ing and healthcare expenditures than previously esti-
mated [4]. Moreover, these untoward effects not only 
become a threat to the life of the patients, but also limit 
the doses that can be administered, ultimately prevent-
ing the use of higher doses that could compensate for 
the limited response of conventional chemotherapy.
Over the past two decades, information garnered 
from cell biology research has strengthened the under-
standing of how malignant cells survive toxic insults 
and become resistant to antineoplastics. Though our 
understanding of the molecular biology of cancer con-
tinues to mature, no successful therapy against drug 
resistance has been achieved to date. In part, this is 
likely because cancer cells thrive in a toxic environ-
ment, largely owing to their ability to exploit an arsenal 
of molecular mechanisms that include an increase in 
drug efflux mechanisms, mutations of drugs targets, 
DNA damage repair processes, activation of alternative 
signaling pathways and evasion of cell death cascades. 
Increased drug efflux, also known as multidrug resis-
tance (MDR), is the principal mechanism by which 
cancer cells develop resistance to chemotherapic drugs. 
Indeed, several cell membrane transporters of the 
large ATP-binding cassette protein family have been 
associated with the MDR phenotype, preventing the 
e ffectiveness of commonly used cancer drugs [5].
P-glycoprotein & its role in MDR
Resistance to chemotherapy medications, such as 
anthracycline may emerge from the action of a vari-
ety of membrane transport proteins that promote the 
extrusion of cytotoxic drugs. The best described is 
P-glycoprotein (P-gp), a 170-kDa adenosine triphos-
phate (ATP)–dependent multispecific drug trans-
porter. Reports linking overexpression of the MDR1 
gene and P-gp to adverse treatment outcome in many 
cancers has implicated this MDR phenotype as an 
important biologic target for pharmacologic modula-
tion [6]. P-gp has been associated with adverse outcomes 
in a variety of solid tumors that include breast, colon, 
bladder and ovarian cancer [7]. Since its discovery in 
1979, numerous modulators of P-gp have been devel-
oped; however, none has been successfully translated 
into the clinic. P-gp is, therefore, recognized as a major 
barrier to the bioavailability of cytotoxic drugs, and as 
a consequence, resistance to chemotherapy remains an 
obstacle to the successful treatment of human cancer.
To date, however, there have only been a handful 
of strategies, which have been tested or are proposed 
to reverse drug resistance. More recent strategies have 
targeted the apoptosis pathway, as well as incorpo-
rating the use of hammerhead ribozymes against the 
MDR1 gene and MDR1-targeted anti-sense oligonu-
cleotides [8]. Thus, despite more than 20 years of effort, 
a large number of clinical trials with P-gp-modulating 
agents have been conducted (so far with poor success), 
as these drugs were vastly ineffective or only effective at 
toxic doses. Hence, it appears that current approaches 
for treating cancer are limited, in part, by the inability 
of drugs to either affect the poorly vascularized regions 
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of tumors or to the development of resistance to the 
chemotherapeutic drug.
Bacteria as cancer therapeutic
The concept of applying bacteria as a cancer therapeu-
tic has been considered as a feasible option for more 
than 150 years. In the late 1800s, observations were 
made by W Busch and F Fehleisen, which associated 
bacterial infections with tumor regression in cancer 
patients [9]. William B Coley came to similar conclu-
sions formed from his observations that a fraction of 
cancer patients who developed postoperative bacterial 
infections went into remission and were cured of their 
tumors [10]. Although the mechanisms behind these 
observations were not well appreciated, scientists at the 
time knew about the immunostimulatory properties 
of bacteria. Furthermore, it has been known for nearly 
60 years that anaerobic bacteria can selectively grow in 
tumors, underscoring the fact that such microbes have 
the potential to overcome many of the delivery barri-
ers, such as impaired circulation and extensive necro-
sis, found in tumors that hinder conventional chemo-
therapeutics [11]. Once inside tumors, these bacteria 
can also effectively activate cells such as macrophages 
and dendritic cells [12].
Recent advances have fueled a resurgence of inter-
est in genetically modified bacteria as drug delivery 
vehicles and/or tumoricidal agents [11]. Several classes 
of bacteria including Listeria, Clostridia and Salmonella 
have been tested as potential therapies for cancer, with 
varying degrees of success [11]. Indeed, novel approaches 
to developing tumor-therapeutic bacteria have recently 
been documented. Sasaki et al., for example, found 
that the anaerobic bacterium Bifidobacterium longum 
could selectively grow in hypoxic regions of solid 
tumors [13]. Additionally, Vogelstein et al. created a 
strain of Clostridium novyi depleted of its lethal toxin 
and showed that intravenous administration of C. 
novyi spores germinated within the avascular regions 
of tumors in mice and destroyed surrounding viable 
tumor cells [14]. Presumably, these bacteria cause tumor 
cell death largely as a result of outcompeting cancer 
cells for nutrients. These examples serve to illustrate 
an intriguing history and useful guidance for the treat-
ment of cancer using live microorganisms. However, 
numerous challenges such as the safety profile and effi-
cacy in larger cohorts of patients remain as obstacles to 
clinical development in the application of such bacteria 
as soldiers of  chemotherapeutic agents.
The foodborne pathogen Salmonella enterica serovar 
Typhimurium (S. Typhimurium) has also been used 
as a therapy, and as a delivery vehicle for cancer thera-
peutics. This facultative anaerobe, can survive in both 
oxygenated and hypoxic conditions, and engage in 
directed motility toward tumor sites, enticed by the 
high concentrations of nutrients available within the 
tumor [15]. Capitalizing on these innate properties, a 
nonpathogenic strain of S. Typhimurium was devel-
oped (VNP2009), which lacks important metabolic 
genes (purI, msbB and xyl) but has been shown to 
migrate and accumulate in tumor sites more at a rate 
1000-times higher compared with that of healthy tis-
sues [16]. Once it reaches tumors, S. Typhimurium is 
thought to out compete cancer cells for essential nutri-
ents. Although this strain was able to retard tumor 
growth and prolong survival in mice, it was not suc-
cessful at slowing tumor growth in the clinic [17]. 
S. Typhimurium was also found to cause the lysis of 
tumor cells by injecting cytotoxic peptides into the 
target cells and facilitating a nonspecific immune reac-
tion [17]. Thus, while S. Typhimurium can localize 
to tumors, the biggest shortcoming of this organism 
as a potential therapeutic is its inability to disperse 
throughout the tumor.
Nevertheless, S. Typhimurium remains a promising 
delivery vehicle because of its tumor specificity, and 
recent advances have further kept alive the hope that 
Salmonella might one day be developed as a clinically 
useful anticancer agent. In a recent study published in 
Nature, Din and colleagues introduced a novel strategy 
that utilizes S. Typhimurium as a potential drug deliv-
ery platform. Unique to this method, these research-
ers engineered a self-limiting strain harnessed with a 
synchronized lysis circuit that allows the organism to 
release, in an oscillatory manner, its genetically encoded 
(toxic) cargo [18]. This synchronized lysis circuit tech-
nology was achieved by inserting a quorum-sensing 
lysis system such that at the end of every lytic cycle, 
a small number of surviving bacteria reseed the grow-
ing population, perpetuating pulsatile delivery cycles. 
While this technology is lauded as a new path in the 
field of targeted drug delivery systems, the authors did 
not report bacterial growth ranges in vivo, raising con-
cerns related to systemic toxicity associated with higher 
bacterial counts. Although S. Typhimurium strains 
were injected intratumorally, the likelihood of bacte-
remia remains high. This would facilitate a sustained 
oscillatory infection of the liver, spleen and bone mar-
“...in vivo proof of concept studies confirmed 
that the Salmonella nanoparticle mimic, 
when used in combination with a common 
cancer  chemotherapeutic (e.g, doxorubicin) 
causes tumor regression in a subcutaneous 
model of m urine colon cancer, as well as in a 
patient-derived xenograft mouse model of breast 
cancer.”
708 Nanomedicine (Lond.) (2017) 12(7) future science group
Commentary    Mercado-Lubo & McCormick
row, which might eventually become toxic for healthy 
tissues colonized by these strains.
Salmonella effector protein as treatment for 
cancer
We have taken a new approach in the use of bacteria as 
a treatment agent for cancer by capitalizing on an unex-
pected resource – host-targeting proteins produced 
by pathogenic bacteria. Salmonella enterica serovar 
Typhimurium is a Gram-negative bacterial pathogen 
that causes a self-limiting gastroenteritis. Infection by 
S. Typhimurium is mediated by an array of effector 
proteins that are delivered sequentially and temporally 
into targeted host cells through a needle-like appara-
tus, the Type Three Secretion System (T3SS). These 
effectors then hijack the structural, immunological and 
life cycle processes of the host cell [19]. T3SS effector 
proteins are therefore often multifunctional proteins 
with several overlapping properties that orchestrate 
specific host cell responses. Salmonella pathogenicity 
likely evolved through the possession of Pathogenic-
ity Islands (SPI). While at least seven separate SPIs 
have been identified, SPI-1 and SPI-2 encode a T3SS 
to deliver effectors that promote pathogenesis and bac-
terial survival [20]. One of these, Salmonella invasion 
protein A (SipA), is a dual function effector protein 
that plays roles in both actin polymerization [21] and 
induction of inflammatory responses [22].
Since Salmonella has evolved to interface with 
numerous biochemical pathways of epithelial cells, it 
seemed reasonable that S. Typhimurium might also 
have evolved mechanisms that interact/interfere with 
MDR transporters that complicate drug treatment. 
Therefore, we examined where the two paths of target-
ing the MDR phenotype, specifically P-gp, and Salmo-
nella’s inherent antitumor properties cross in regard to 
cancer therapeutics and host–tumor/pathogen interac-
tions. We discovered that colonization of human colon 
cancer cell lines (that overexpress P-gp) by wild-type S. 
Typhimurium leads to a profound functional decrease 
and loss of protein expression in the MDR protein 
transporter, P-gp. Of note, this is the first observation 
to link a microorganism that is targeted to tumors with 
the regulation of MDR transporters.
More recently, our work has uncovered that the S. 
Typhimurium T3SS effector protein, SipA, is respon-
sible for the downregulation of the MDR transporter 
P-gp. In fact, this protein interacts with a broad spec-
trum of tumors (colon, breast, bladder and B-cell lym-
phoma), inhibiting the cellular mechanisms that allow 
cancer cells to develop resistance to chemotherapeutic 
drugs. In previous contributions, we have revealed 
that in Salmonella-infected epithelial cells P-gp 
expression is downregulated without a corresponding 
decrease in P-gp mRNA. This observation supports 
a mechanism of P-gp protein cleavage from the cell 
membrane rather than the regulation of gene expres-
sion, and is consistent with prior studies using human 
T-lymphoblastoid CEM cells, which were the first to 
describe that P-gp downregulating can occur through 
a process involving protein degradation [23]. The abil-
ity of the S. Typhimurium effector, SipA, to modu-
late P-gp depends on its ability to activate caspase-3 
(CASP3) [24], and further supports our  observation 
that SipA is an inducer of apoptosis.
We, therefore, began to consider whether SipA, 
itself, could be used as an effective P-gp modulator 
(and without the undesired side effects). We first 
showed that purified SipA not only improved the 
cytotoxic activity of known chemotherapeutic drugs 
(e.g., doxorubicin and vinblastine), which are also 
P-gp substrates, but also increased the intracellular 
retention of these drugs. Second, we built a Salmo-
nella nanoparticle mimic made by fusing a 15 nm 
gold nanoparticle with a SipA corona (SipA-AuNP) 
to be applied as an effective therapeutic adjuvant, as 
a method to increase cancer cell sensitivity to chemo-
therapeutics. To create this novel drug/therapeutic 
protein-delivery system, we used gold nanoparticles 
(AuNP) as a scaffold. AuNPs have been used in ther-
apy as colloidal pharmaceuticals with a long history 
of intra-articular application for treatment of chronic 
arthritis, and display the following key properties tai-
lored for delivery vehicles: the gold core is essentially 
inert; AuNPs are <100 nm in size, which enhances 
their permeation and retention effect, thereby allow-
ing these particles to efficiently extravasate into 
interstitial spaces. The end result is a much higher 
concentration of payload therapeutic at the tumor 
site relative to the same administered dosage of free 
drug [25]; nanoparticles as drug delivery systems have 
been shown to circumvent P-gp-mediated MDR by 
reducing MDR1 gene expression [26]; nanoparticles 
can be fabricated in highly divergent ways to provide 
various desirable delivery modes, such as stabilizing 
conjugated proteins [27], DNA [28] and drugs [29]. They 
also can promote long systemic circulation lifetime, 
along with a higher tumor targeting ability, intracel-
lular thiol (e.g., glutathione), controllable payload 
release and excellent solubility qualities.
“The SipA-nanobug was designed to  surmount 
many of the key challenges c ommonly a ssociated 
with traditional or even  unconventional 
 chemotherapeutic strategies with  enhanced 
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While advances have been made in utilizing AuNPs 
as a delivery system for genetic material and small mol-
ecules, the carriage of functional proteins on nanopar-
ticles with retention or enhanced activity has remained 
largely unchartered primarily because of the complexi-
ties surrounding protein recognition and structure 
retention. To bypass this limitation, we engineered 
surface ligands for direct conjugation of SipA to the 
AuNPs. Selected ligands containing biocompatible 
oligo(ethylene glycol) spacers between SipA and the 
nanoparticle reduce nonspecific interactions, as well 
as provide additional degrees of freedom and polyva-
lency for enhancing SipAs activities. This method has 
yielded conjugates that are able to prevent this protein 
from dissociation or aggregation, and which preserve 
the conformation/structure of SipA.
Using this strategy, the SipA-AuNPs significantly 
increased the stability of surface bound SipA proteins, 
and reduced P-gp expression across numerous cancer 
cells at a SipA dose nearly 500 times lower than free 
unbound SipA. In addition, in vivo proof of concept 
studies confirmed that the Salmonella nanoparticle 
mimic, when used in combination with a common 
cancer chemotherapeutic (e.g, doxorubicin) causes 
tumor regression in a subcutaneous model of murine 
colon cancer, as well as in a patient-derived xenograft 
mouse model of breast cancer. Significantly, in these 
models it is notable that the efficacy of the chemother-
apeutic drug, doxorubicin, was profoundly increased, 
as the dose of the agent required to reach tumor reduc-
tion was lowered between two- to ten-fold compared 
with the dose conventionally used in the field. This 
effect is most likely due to the 70% reduction of P-gp 
expression observed in these tumors [30].
The SipA-nanobug was designed to surmount many 
of the key challenges commonly associated with tradi-
tional or even unconventional chemotherapeutic strat-
egies with enhanced pharmacokinetic and biodistribu-
tion proficiencies. Nonetheless, we acknowledge that 
the development of drug resistance in cancer cells is 
a rather complex and multifactorial process. That is, 
the molecular mechanisms activated to protect can-
cer cells against toxic compounds and allow them to 
thrive during their clonal expansion certainly extend 
beyond a single mechanism of drug resistance. There is 
also the additional concern that because ATP-binding 
cassette transporters are a large family of highly con-
served proteins, that one transporter can compensate 
if another is blocked. Regardless, the core of our drug 
technology is uniquely designed to combat drug resis-
tance which should improve the effectiveness of the 
treatment. Moreover, given that Salmonella has co-
evolved with the human host for nearly 2 million years 
and thus may exploit host machinery not accessible by 
other drug-based methods, it is not unreasonable to 
envisage that SipA may afford unique advantages with 
respect to previously developed small molecules that 
target MDR. Overall, engineering of this semisyn-
thetic Salmonella nanoparticle mimic introduces a new 
platform technology that has the capacity to be applied 
to various chemotherapeutic drugs to overcome MDR 
in tumors.
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